Status:

RECRUITING

Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)

Lead Sponsor:

Ion Beam Applications

Conditions:

Solid Tumor, Adult

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device. The trial aims to assess the safety and efficacy of PROTEUS® P...

Detailed Description

The trial is structured in two distinct phases. Phase 1 - Clinical Trial: This phase spans from the initial screening through to 90 days post-treatment. Its primary objective is to assess the efficacy...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (main):
  • Clinically diagnosed with benign/malignant intracranial tumor and malignant solid tumor of head and neck, chest, abdomen, spine, pelvic cavity and limbs
  • At least 1 lesion of the tumor to be treated is measurable according to RECIST criteria
  • Expected survival time of more than 6 months
  • ECOG performance status of 0 to 2
  • Negative pregnancy test (HCG) results within 7 days prior to the first treatment for females of childbearing potential
  • Exclusion Criteria (main):
  • Contraindications to radiation therapy
  • Presence of other uncontrolled tumors other than the tumor to be treated
  • Implants and devices in the treatment area
  • Re-irradiation
  • Other conditions that are not suitable for inclusion, as judged by the investigator.

Exclusion

    Key Trial Info

    Start Date :

    April 29 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 31 2031

    Estimated Enrollment :

    47 Patients enrolled

    Trial Details

    Trial ID

    NCT07137195

    Start Date

    April 29 2025

    End Date

    July 31 2031

    Last Update

    August 22 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Hebei Yizhou Cancer Hospital

    Zhuozhou, Hebei, China